Hong Kong Auto Components Stock News

Jacobson Pharma (SEHK:2633) has reported first half FY 2026 revenue of HK$766.6 million and basic EPS of HK$0.071, with trailing twelve month revenue at HK$1.6 billion and EPS at HK$0.151, giving investors a clear view of its recent earnings power. The company has seen half yearly revenue move from HK$810.0 million and EPS of HK$0.071 in the first half of FY 2025 to HK$766.9 million and EPS of HK$0.081 in the second half of FY 2025. This sets the stage for the latest numbers to be read...

Lotus Horizon Holdings (SEHK:6063) has opened FY 2026 with first half revenue of HK$120.0 million and basic EPS of HK$0.000647, against a trailing 12 month picture where revenue was HK$226.0 million and the company reported a net loss of HK$3.3 million and EPS of HK$0.0017. Over the past three reported half year periods, revenue has moved from HK$130.7 million with EPS of HK$0.001009 in 1H FY 2025 to HK$129.2 million with EPS of HK$0.000587 in 2H FY 2025, and then to HK$120.0 million with EPS...

Global markets have been influenced by key developments, such as the Federal Reserve's decision to hold interest rates steady and the Bank of Japan's rate hike to a 31-year high. Against this backdrop, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors seeking growth potential at lower price points. While the term "penny stocks" may seem outdated, these investments can still present valuable prospects when they exhibit strong...

As global markets navigate a complex landscape of monetary policy shifts and geopolitical developments, Asian equities have shown resilience amid mixed economic signals. With Japan's stock markets surging to new heights and China grappling with uneven recovery, investors are keenly observing opportunities for undervalued stocks that might offer significant upside potential. Identifying stocks trading below their intrinsic value can be particularly appealing in such uncertain times, as these...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Viewing insider transactions for Vala Inc.'s ( HKG:2051 ) over the last year, we see that insiders were net buyers...

Insiders who bought CN¥6.69m worth of Xiabuxiabu Catering Management (China) Holdings Co., Ltd.'s ( HKG:520 ) stock at...

Recent Performance Snapshot for Tencent Holdings stock Tencent Holdings (SEHK:700) has drawn investor attention after a period where the stock declined 4.2% over the past day, 7.3% over the past week and about 6% over the past month. Over the past 3 months, Tencent Holdings is down about 17.9%, with the year to date return showing a decline of 33.4%. On a 1 year basis, the total return is down 17.6%, while the 3 year total return stands at 25.1% and the 5 year total return reflects a decline...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Market forces rained on the parade of China Tobacco International (HK) Company Limited ( HKG:6055 ) shareholders today...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Tristate...

Nameson Holdings (SEHK:1982) has just reported its FY 2026 first half results with revenue of HK$2.8b and basic EPS of HK$0.15, setting the tone for how the rest of the year could unfold. The company has seen revenue move from HK$2.8b with EPS of HK$0.13 in FY 2025 first half to HK$1.6b with EPS of HK$0.02 in FY 2025 second half before reaching HK$2.8b and EPS of HK$0.15 in the latest FY 2026 first half, giving investors a clearer read on how earnings power is tracking through the cycle. With...

Growth has become harder to find as major economies send mixed signals, from weak European PMIs and contracting UK services to patchy strength across Asia and Latin America. In this kind of stop start backdrop, many investors are looking for companies where management is clearly aligned with shareholders and analysts see room for further expansion. The Fast Growing Stocks With High Insider Ownership screener focuses on exactly that combination. It highlights businesses where insiders have...

JBM (Healthcare) (SEHK:2161) has posted its FY 2026 first half results with revenue of HK$429.6 million and basic EPS of HK$0.141, setting the stage for how investors assess the latest move in profitability. The company has reported revenue of HK$398.9 million in FY 2025 H1, HK$383.3 million in FY 2025 H2, and HK$429.6 million in FY 2026 H1, while basic EPS was HK$0.116 in FY 2025 H1, HK$0.108 in FY 2025 H2, and HK$0.141 in the latest half. These figures sit against a slightly softer net...

Beisen Holding (SEHK:9669) has reported its FY 2026 first half with revenue of C¥516.0 million and a loss per share of C¥0.03, alongside trailing twelve month revenue of C¥1.10 billion and a TTM loss per share of C¥0.03. The company has seen revenue move from C¥436.6 million in 1H FY 2025 to C¥508.5 million in 2H FY 2025 and then to C¥516.0 million in 1H FY 2026. Losses per share shifted from C¥0.14 in 1H FY 2025 to C¥0.07 in 2H FY 2025 and C¥0.03 in 1H FY 2026, setting up an earnings season...

Why the SSE 180 Index Addition Matters for COSCO SHIPPING Energy Transportation COSCO SHIPPING Energy Transportation (SEHK:1138) was recently added to the SSE 180 Index, a move that can draw more attention from institutional investors and index-tracking funds. This index inclusion often leads to higher visibility in the domestic market, which can influence trading volumes and liquidity. For existing and potential shareholders, the change raises questions about how the stock’s fundamentals...

Why JF SmartInvest Holdings’ Rebrand Is Drawing Fresh Attention JF SmartInvest Holdings (SEHK:9636) recently rebranded from JF Wealth Holdings, highlighting a clearer focus on online investment decision-making solutions at a time when the stock has retreated over the past month and the past 3 months. See our latest analysis for JF SmartInvest Holdings. For context, JF SmartInvest Holdings’ share price has fallen year to date. Its 1-day share price return of 13.08% stands out against a 30-day...

Amidst a backdrop of shifting monetary policies and mixed economic signals in Asia, investors are closely watching regional markets for opportunities. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their potential for substantial growth when supported by strong financials. While the term "penny stock" may seem outdated, the investment potential remains significant as these companies can offer unique value propositions that larger firms...

The recent 15% drop in Newlink Technology Inc.'s ( HKG:9600 ) stock could come as a blow to insiders who purchased...

While Madison Holdings Group Limited ( HKG:8057 ) shareholders have had a good week with the stock up 17%, they...

As the Asian markets navigate a complex landscape marked by geopolitical developments and monetary policy shifts, investors are on the lookout for opportunities that align with current economic conditions. Penny stocks, though often seen as relics of speculative trading, still offer potential when backed by strong financials and growth prospects. This article explores three penny stocks in Asia that stand out for their robust fundamentals, offering a unique opportunity for investors seeking...

China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate. This approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its...

In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China. Beyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful...